{"id":"W4286491901","doi":"10.1111/bjh.18368","title":"A phase 2, multicentre, open‐label trial (<scp>ACE‐LY</scp>‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Adverse effect; Discontinuation; Refractory (planetary science); Hazard ratio; Febrile neutropenia; Phases of clinical research; Progression-free survival; Surgery; Confidence interval; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001654983,0.001012265,0.0009963822,0.0003406362,0.0002371346,0.0005964004,0.000458055,0.0008398264,0.002772],"category_scores_gemma":[0.0008084991,0.0002769719,0.0008180724,0.0002719515,0.0005793262,0.0004653475,0.000315124,0.002012298,0.0006159572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005671637,"about_ca_system_score_gemma":0.0008478772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006234536,"about_ca_topic_score_gemma":0.002383275,"domain_scores_codex":[0.9995725,0.000267442,0.00001576517,0.0000489146,0.00003164713,0.00006371477],"domain_scores_gemma":[0.9994425,0.0001274288,0.000112889,0.00004301672,0.00002877263,0.0002453923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6436296,0.04469125,0.01651564,0.001227014,0.001568272,0.0008091471,0.0005394164,0.002041154,0.07588442,0.0005514842,0.008590917,0.2039517],"study_design_scores_gemma":[0.7216419,0.247287,0.02105469,0.00003353502,0.0003071589,0.0005576214,0.0000435757,0.001382519,0.003916449,0.0002238333,0.00351908,0.00003254953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924388,0.001814872,0.0006008264,0.0004373144,0.00007648578,0.001803464,0.0008733085,0.00007717872,0.001877837],"genre_scores_gemma":[0.9912293,0.0009878813,0.001621805,0.0008456362,0.0001836597,0.001396665,0.002144374,0.00001911117,0.00157155],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002772,"threshold_uncertainty_score":0.009273291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03317684450859787,"score_gpt":0.3337321386956786,"score_spread":0.3005552941870808,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}